Theriva Biologics doses first patient in VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC

Theriva Biologics, Inc.

First patient dosed in VIRAGE2 Phase 2a trial evaluating more frequent repeated dosing of VCN-01 in first-line metastatic PDAC.
Enrollment completion expected H2 2026; initial pharmacodynamic and safety/tolerability data anticipated by Q3 2027.
Trial based on VIRAGE Phase 2b data where 2 doses of VCN-01 + SoC showed improved overall survival, progression-free survival, and duration of response vs SoC alone.
EMA and FDA feedback recognized potential of repeated VCN-01 dosing to improve clinical outcomes.
Results will inform dosing regimen for potential future pivotal Phase 3 trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.